Trial Profile
A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Partial epilepsies; Tuberous sclerosis
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms EXIST-3
- Sponsors Novartis; Novartis Pharmaceuticals
- 25 Oct 2021 Results (n=244) the long-term efficacy and safety of everolimus from the EXIST-3 study at the end of the postextension phase, published in the Epilepsia
- 22 Aug 2019 Results published in the Novartis Media Release.
- 22 Aug 2019 According to an Novartis media release, everolimus was approved in Japan as an adjunctive treatment of for patients aged two years and older for partial-onset seizures associated with tuberous sclerosis complex (TSC). This approval was based on the safety and efficacy data from this EXIST-3 trial.